Floatz logo

Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide

Brain Glioblastoma

Oblato, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Brain Glioblastoma cohort.

Asset / SponsorPhaseRating
Tvi-Brain-1
TVAX Biomedical
Phase 2/3B
Ruxolitinib
Baptist Health South Florida
Phase 2CCC
Belinostat
Emory University
Phase 2CCC
Avelumab
Clinique Neuro-Outaouais
Phase 2CCC
Pembrolizumab
University Hospital, Geneva
Phase 1/2CCC

View all 22 →

Same molecule, other indications

Disodium 4-((Tert-Butylimino)Methyl)Benzene-1,3-Disulfonate N-Oxide is also rated in:

malignant gliomaActive
BB
Indicative · Phase 2
64 / 100
View asset →
astrocytic tumorActive
CCC
Indicative · Phase 1/2
52 / 100
View asset →
glioblastomaActive
CC
Indicative · Phase 1/2
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →